参松养心胶囊辅治冠心病并心律失常临床观察

目的:观察参松养心胶囊辅治冠心病并心律失常的疗效。方法:88例依据不同治疗方式分为对照组43例和观察组45例,两组均给予琥珀酸美托洛尔缓释片治疗,观察组加用参松养心胶囊治疗。结果:观察组总有效率高于对照组(P<0.05)。治疗后两组血清PCT、CRP、IL-6水平低于治疗前(P<0.05),且观察组低于对照组(P<0.05)。治疗后两组血浆比黏度、纤维蛋白原、血细胞比容水平低于治疗前(P<0.05),且观察组低于对照组(P<0.05)。两组不良反应发生率比较无统计学意义(P>0.05)。结论:参松养心胶囊辅治冠心病并心律失常可提高疗效,且安全。

Objective:To observe the curative effect of Shensong Yangxin Capsule in the treatment of coronary heart disease and arrhythmia.Methods:Eighty-eight cases were divided into the control group(43 cases)and the observation group(45 cases)according to different treatment methods.Both groups were treated with metoprolol succinate sustainedrelease tablets and the observation group was treated with Shensong Yangxin Capsule in addition.Results:The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of serum PCT,CRP and IL-6 in the two groups were lower than those before treatment(P<0.05),and those in the observation group were lower than the control group(P<0.05).After treatment,the levels of plasma specific viscosity,fibrinogen and hematocrit in the two groups were lower than those before treatment(P<0.05),and those in the observation group were lower than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Shensong Yangxin Capsule could improve the curative effect in the treatment of coronary heart disease and arrhythmia,with safety.